pone.0177646.g006.tif (514.87 kB)
Download file

Network and pairwise meta-analyses for myocardial infarction of oral antidiabetic drugs.

Download (514.87 kB)
posted on 25.05.2017, 17:39 by Gyeongsil Lee, Seung-Won Oh, Seung-Sik Hwang, Ji Won Yoon, Sungchan Kang, Hee-Kyung Joh, Hyuktae Kwon, Jeehyun Kim, Danbee Park

The analyses of myocardial infarction risk included data from not only published article as non-fatal myocardial infarction but unpublished reports as acute myocardial infarction or myocardial infarction as severe adverse events. Traditional pairwise (upper right side) and network (lower left side) meta-analytic results are depicted for the cardiovascular-related mortality. Outcome of meta-analysis is expressed as relative risks (RRs) (95% confidence intervals) in the case of pairwise meta-analysis and (95% credible intervals) in the case of network meta-analysis. For the pairwise meta-analysis, RRs of less than 1 indicate that the drug located in the column is safer. For the network meta-analysis, RRs of less than 1 indicate that the drug located in the row is safer. Bold results indicate statistical significance. The analyses of all-cause mortality risk included data from 70 RCTs but the sum of total studies is 73 because two trials split in four. One is A Diabetes Outcome Progression Trial (ADOPT) [29], three-arm (metformin, glyburide, and rosiglitazone) study, which split in three. The other is Rosiglitazone Evaluated for Cardiovascular Outcomes and regulation of Glycaemia in Diabetes (RECORD) [31] which split in two after searching reports as separated by metformin or sulfonylurea at ClinicalTrials.gov website. TZD: thiazolidinedione. DPP4: dipeptidyl peptidase-4. SGLT2: sodium glucose cotransporter-2.